ERBB2 and neoplasm: Studies using an in vivo A549 NSCLC xenograft model and in vitro NSCLC cell lines (A549 and H1650) revealed anti-tumor effects of HER2-targeted CAR-T cells, including decreased tumor growth but not complete tumor elimination (44, 45).